Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers

Biomarkers

Volumn 17, Issue 4, 2012, Pages 362-371

  Kiyamova, Ramziya ^a   Garifulin, Oleg ^a   Gryshkova, Vitalina ^a   Kostianets, Olga ^a   Shyian, Maksym ^a   Gout, Ivan ^b   Filonenko, Valeriy ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen; Autoantibody; Immunodiagnostics

Indexed keywords

ANTIGEN; ARP1 ACTIN RELATED PROTEIN 1 HOMOLOG A; AUTOANTIBODY; BUTYROPHILIN SUBFAMILY 3 MEMBER A3; CATHEPSIN H; CG016 ANTIGEN; FK506 BINDING PROTEIN 4; FXYD DOMAIN CONTAINING ION TRANSPORT REGULATOR 3; TESTES SPECIFIC A2 HOMOLOG; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; ASSAY; CANCER DIAGNOSIS; COLON CANCER; CONTROLLED STUDY; DNA LIBRARY; HUMAN; SCREENING; SEROLOGY; THYROID CANCER;

ADULT; AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; EARLY DETECTION OF CANCER; GENE LIBRARY; HUMANS; MIDDLE AGED; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861598505     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.677476     Document Type: Article

References (48)

1. Anderson KS, LaBaer J. (2005). The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4:1123-1133.
2. Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J. (2008). Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7:1490-1499.
3. Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S, Tanic N. (2010). Identification of genes associated with nonsmall- cell lung cancer promotion and progression. Lung Cancer 67:151-159.
4. Bau DT, Yang MD, Tsou YA, Lin SS, Wu CN, Hsieh HH, Wang RF, Tsai CW, Chang WS, Hsieh HM, Sun SS, Tsai RY. (2010). Colorectal cancer and genetic polymorphism of DNA double-strand break repair gene XRCC4 in Taiwan. Anticancer Res 30:2727-2730.
5. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF. (2011). Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22:383-389.
6. Behrends U, Schneider I, Rössler S, Frauenknecht H, Golbeck A, Lechner B, Eigenstetter G, Zobywalski C, Müller-Weihrich S, Graubner U, Schmid I, Sackerer D, Späth M, Goetz C, Prantl F, Asmuss HP, Bise K, Mautner J. (2003). Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer 106:244-251.
7. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. (2007). Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6:1115-1122.
8. Casiano CA, Mediavilla-Varela M, Tan EM. (2006). Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 5:1745-1759.
9. Chomczynski P, Sacchi N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
10. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E. (2005). Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci USA 102:9601-9606.
11. Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J. (2009a). Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 15:4733-4741.
12. Desmetz C, Cortijo C, Mangé A, Solassol J. (2009b). Humoral response to cancer as a tool for biomarker discovery. J Proteomics 72:982-988.
13. Desmetz C, Maudelonde T, Mangé A, Solassol J. (2009c). Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev Proteomics 6:377-386.
14. Devitt G, Meyer C, Wiedemann N, Eichmüller S, Kopp-Schneider A, Haferkamp A, Hautmann R, Zöller M. (2006). Serological analysis of human renal cell carcinoma. Int J Cancer 118:2210-2219.
15. Ehrlich JR, Qin S, Liu BC. (2006). The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 1:452-460.
16. Gao Y, Ferguson DO, Xie W, Manis JP, Sekiguchi J, Frank KM, Chaudhuri J, Horner J, DePinho RA, Alt FW. (2000). Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404:897-900.
17. Garifulin OM, Kykot VO, Gridina NY, Kijamova RG, Gout IT, Filonenko VV. (2003). SEREX-analysis of three colon cancer cases. Exp Oncol 25:128-131.
18. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M. (2003). Characterization of several leukemiaassociated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224-231.
19. Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jäger D. (2010). Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 107:5088-5093.
20. Gocheva V, Chen X, Peters C, Reinheckel T, Joyce JA. (2010). Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biol Chem 391:937-945.
21. Gunawardana CG, Diamandis EP. (2007). High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 249:110-119.
22. Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M. (2007). Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 1107:223-230.
23. Heisel SM, Ketter R, Keller A, Klein V, Pallasch CP, Lenhof HP, Meese E. (2008). Increased seroreactivity to glioma-expressed antigen 2 in brain tumor patients under radiation. PLoS ONE 3:e2164.
24. Ikematsu N, Yoshida Y, Kawamura-Tsuzuku J, Ohsugi M, Onda M, Hirai M, Fujimoto J, Yamamoto T. (1999). Tob2, a novel antiproliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases. Oncogene 18:7432-7441.
25. Kyyamova RG, Rodnin NV, Garifulin OM, Tykhonkova IA, Koroleva EP, Malets MS, Gout IT, Filonenko VV (2004) Allogeneic screening of tumor antigens from thyroid cancer cDNA libraries.Biopolym Cell 20:151-157
26. Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ. (2003). Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 100:2651-2656.
27. Li L, Wang K, Dai L, Wang P, Peng XX, Zhang JY. (2008). Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. Mol Med Report 1: 589-594.
28. Ludwig N, Keller A, Heisel S, Leidinger P, Klein V, Rheinheimer S, Andres CU, Stephan B, Steudel WI, Graf NM, Burgeth B, Weickert J, Lenhof HP, Meese E. (2009). Improving seroreactivity-based detection of glioma. Neoplasia 11:1383-1389.
29. Matsuda S, Kawamura-Tsuzuku J, Ohsugi M, Yoshida M, Emi M, Nakamura Y, Onda M, Yoshida Y, Nishiyama A, Yamamoto T. (1996). Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene 12:705-713.
30. Nolen B, Winans M, Marrangoni A, Lokshin A. (2009). Aberrant tumorassociated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. J Immunol Methods 344:116-120.
31. Pallasch CP, Struss AK, Munnia A, König J, Steudel WI, Fischer U, Meese E. (2005). Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 117:456-459.
32. Qin S, Qiu W, Ehrlich JR, Ferdinand AS, Richie JP, O'leary MP, Lee ML, Liu BC. (2006). Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6:3199-3209.
33. Ramachandran N, Hainsworth E, Bhullar B, Eisenstein S, Rosen B, Lau AY, Walter JC, LaBaer J. (2004). Self-assembling protein microarrays. Science 305:86-90.
34. Rodnin NV, Tykhonkova IO, Nemazany IO, Gorlova LM, Komissarenko IV, Palchevskiy SS, Kuharenko OP, Drobot LB, Matsuka GH, Filonenko VV, Gout IT. (2000). Serological identification of autoimmune reactive antigens in human thyroid cancer cells. Exp Oncol 22:135-138.
35. Rodnin NV, Tykhonkova IO, Kyyamova RG, Garifulin OM, Gout IT, Filonenko VV. (2003). Identification of tumor-associated antigens in human thyroid papillar carcinoma. Biopolym Cell 19:541-547.
36. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci O, Sahin U, Pfreundschuh M, Old LJ. (1998). Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76:652-658.
37. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jäger D, Jäger E, Knuth A, Old LJ. (2002). Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 62:4041-4047.
38. Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, Glickman JN, Chirieac LR, Hartman ML, Taillon BE, Du L, Bouffard P, Kingsmore SF, Miller NA, Farmer AD, Jensen RV, Gullans SR, Bueno R. (2008). Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci USA 105:3521-3526.
39. Tan EM. (2001). Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108:1411-1415.
40. Tan HT, Low J, Lim SG, Chung MC. (2009). Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880-6904.
41. Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. (2006). Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 29:567-575.
42. de Visser KE, Eichten A, Coussens LM. (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24-37.
43. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. (2005). Autoantibody signatures in prostate cancer. N Engl J Med 353:1224-1235.
44. Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, Peng JR, Zhao HT, Rui JA, Leng XS, Cebon J, Burgess AW, Chen WF. (2002). Large scale identification of human hepatocellular carcinomaassociated antigens by autoantibodies. J Immunol 169:1102-1109.
45. Yamada K, Senju S, Nakatsura T, Murata Y, Ishihara M, Nakamura S, Ohno S, Negi A, Nishimura Y. (2001). Identification of a novel autoantigen UACA in patients with panuveitis. Biochem Biophys Res Commun 280:1169-1176.
46. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136-143.
47. Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. (2007). Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46:107-114.
48. Zhang Z, Pang ST, Kasper KA, Luan C, Wondergem B, Lin F, Chuang CK, Teh BT, Yang XJ. (2011). FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomark Insights 6:17-26.